Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
Authors:
- Matthew J. ManeenMMMatthew J. Maneen
- Stephen M. StahlSSStephen M. Stahl
- 1 January 2009
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 6 (1) , 78-85
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonismInternational Journal of Neuropsychopharmacology, 2007
- Molecular Targets for Treating Cognitive Dysfunction in SchizophreniaSchizophrenia Bulletin, 2007
- Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmissionPharmacology & Therapeutics, 2007
- Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patientsCurrent Opinion in Psychiatry, 2006
- The NIMH-MATRICS Consensus Statement on Negative SymptomsSchizophrenia Bulletin, 2006
- Modulation of dopamine release by striatal 5‐HT2C receptorsSynapse, 2005
- Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMolecular Psychiatry, 2004
- What's atypical about atypical antipsychotic drugs?Current Opinion in Pharmacology, 2004
- Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in RatsScience, 1998
- Cellular localization of the 5-HT receptor in primate brain neurons and glial cellsNeuropsychopharmacology, 1996